0001415889-22-008608.txt : 20220815
0001415889-22-008608.hdr.sgml : 20220815
20220815161639
ACCESSION NUMBER: 0001415889-22-008608
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220811
FILED AS OF DATE: 20220815
DATE AS OF CHANGE: 20220815
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Martin Samuel Bates
CENTRAL INDEX KEY: 0001709024
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-15006
FILM NUMBER: 221165833
MAIL ADDRESS:
STREET 1: C/O CELLDEX THERAPEUTICS, INC.
STREET 2: 53 FRONTAGE ROAD, SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Celldex Therapeutics, Inc.
CENTRAL INDEX KEY: 0000744218
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 133191702
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 53 FRONTAGE ROAD
STREET 2: SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
BUSINESS PHONE: 908-200-7500
MAIL ADDRESS:
STREET 1: 53 FRONTAGE ROAD
STREET 2: SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
FORMER COMPANY:
FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC
DATE OF NAME CHANGE: 19980828
FORMER COMPANY:
FORMER CONFORMED NAME: T CELL SCIENCES INC
DATE OF NAME CHANGE: 19920703
4
1
form4-08152022_010833.xml
X0306
4
2022-08-11
0000744218
Celldex Therapeutics, Inc.
CLDX
0001709024
Martin Samuel Bates
C/O CELLDEX THERAPEUTICS, INC.
53 FRONTAGE ROAD, SUITE 220
HAMPTON
NJ
08827
false
true
false
false
SVP AND CFO
Common Stock
2022-08-11
4
M
0
2453
9.0165
A
26831
D
Common Stock
2022-08-11
4
S
0
2453
37.0389
D
24378
D
Common Stock
2022-08-12
4
M
0
3876
9.0165
A
28254
D
Common Stock
2022-08-12
4
M
0
13671
2.78
A
41925
D
Common Stock
2022-08-12
4
S
0
14261
36.7649
D
27664
D
Common Stock
2022-08-12
4
S
0
2065
35.3766
D
25599
D
Common Stock
2022-08-12
4
S
0
1221
34.6206
D
24378
D
Incentive Stock Option (Right to Buy)
9.0165
2022-08-11
4
M
0
2453
0
D
2028-06-13
Common Stock
2453
7077
D
Incentive Stock Option (Right to Buy)
9.0165
2022-08-12
4
M
0
3876
0
D
2028-06-13
Common Stock
3876
3201
D
Incentive Stock Option (Right to Buy)
2.78
2022-08-12
4
M
0
13671
0
D
2029-06-19
Common Stock
13671
10750
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.26 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.24 to $37.23 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.88 to $35.82 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.31 to $34.81 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
As of June 13, 2022, the option is fully vested.
25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
/s/ Anthony S. Marucci, attorney-in-fact for Samuel Bates Martin
2022-08-15